Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Is undergoing matched or single-antigen mismatched unrelated-donor myeloablative transplant for the treatment of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML); Is less than or equal to (\<=) 60 years of age.~   For the cohort after RP2D~2. Is undergoing matched or single-antigen mismatched related or unrelated-donor transplant and receiving myeloablative conditioning or RIC for the treatment of hematologic malignancies or myeloproliferative neoplasms; Is less than or equal to (\<=) 75 years of age.~Exclusion Criteria:~1. Has received prior allogeneic transplants or who are planned to undergo umbilical cord blood transplant, receive ex vivo T-cell-depleted hematopoietic stem cells (HSCs), received any in vivo T-cell depleting antibodies, or non-myeloablative conditioning.~2. Has active cerebral/meningeal disease, active cytomegalovirus (CMV) colitis, or signs and symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.~3. Is undergoing transplant for the treatment of nonmalignant hematological disorders (for example: aplastic anemia, sickle cell anemia, thalassemias, Fanconi anemia).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Vedolizumab 75 mg (Type: EXPERIMENTAL): Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
- Cohort 2: Vedolizumab 300 mg (Type: EXPERIMENTAL): Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
- Cohort 3: Vedolizumab Dose 1 (Type: EXPERIMENTAL): Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.

Based on this trial design, predict the completion outcome and termination type (if applicable).